← Back to Screener
Ernexa Therapeutics Inc. Common Stock (ERNA)
Price$0.20
Favorite Metrics
Price vs S&P 500 (26W)-90.18%
Price vs S&P 500 (4W)-40.62%
Market Capitalization$5.49M
All Metrics
Book Value / Share (Quarterly)$0.31
P/TBV (Annual)0.78x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-69.14%
Cash Flow / Share (Quarterly)$-0.90
Price vs S&P 500 (YTD)-86.88%
Gross Margin (TTM)83.51%
Net Profit Margin (TTM)-7720.96%
EPS (TTM)$-3.24
10-Day Avg Trading Volume0.87M
EPS Excl Extra (TTM)$-3.24
Revenue Growth (5Y)-51.31%
EPS (Annual)$-2.23
Dividend / Share (Annual)$0.00
ROI (Annual)-446.97%
Gross Margin (Annual)83.51%
Net Profit Margin (5Y Avg)-7921.03%
Cash / Share (Quarterly)$0.24
ROA (Last FY)-241.41%
Revenue Growth TTM (YoY)-99.83%
EBITD / Share (TTM)$-2.24
ROE (5Y Avg)-971.78%
Operating Margin (TTM)-6600.34%
Cash Flow / Share (Annual)$-0.90
P/B Ratio2.29x
P/B Ratio (Quarterly)3.92x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)7.48x
Net Interest Coverage (TTM)-5.41x
ROA (TTM)-228.54%
EPS Incl Extra (Annual)$-2.23
Current Ratio (Annual)1.01x
Quick Ratio (Quarterly)0.88x
3-Month Avg Trading Volume1.26M
52-Week Price Return-94.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.36
P/S Ratio (Annual)9.43x
Asset Turnover (Annual)0.11x
52-Week High$4.05
Operating Margin (5Y Avg)-7549.30%
EPS Excl Extra (Annual)$-2.23
CapEx CAGR (5Y)-32.80%
Tangible BV CAGR (5Y)26.77%
26-Week Price Return-86.20%
Quick Ratio (Annual)0.88x
13-Week Price Return-85.45%
Total Debt / Equity (Annual)0.31x
Current Ratio (Quarterly)1.01x
Enterprise Value$4.353
Revenue / Share Growth (5Y)-71.73%
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-51.48%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)21.45x
Pretax Margin (Annual)-7647.59%
Cash / Share (Annual)$0.24
3-Month Return Std Dev145.07%
Gross Margin (5Y Avg)2.78%
Net Income / Employee (TTM)$-2
ROE (Last FY)-586.59%
Net Interest Coverage (Annual)-5.47x
EPS Basic Excl Extra (Annual)$-2.23
P/FCF (TTM)3.33x
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.31x
EPS Incl Extra (TTM)$-3.24
Receivables Turnover (Annual)0.00x
ROI (TTM)-158.02%
P/S Ratio (TTM)9.43x
Pretax Margin (5Y Avg)-7920.90%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.36
Price vs S&P 500 (52W)-123.83%
Year-to-Date Return-84.24%
5-Day Price Return-8.25%
EPS Normalized (Annual)$-2.23
ROA (5Y Avg)-325.96%
Net Profit Margin (Annual)-7652.75%
Month-to-Date Return-5.45%
Cash Flow / Share (TTM)$-4.09
EBITD / Share (Annual)$-2.24
Operating Margin (Annual)-6548.80%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-784.25%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.24
P/TBV (Quarterly)0.78x
P/B Ratio (Annual)3.92x
Dividend / Share (TTM)$0.00
Inventory Turnover (TTM)33.29x
Pretax Margin (TTM)-7718.38%
Book Value / Share (Annual)$0.31
Price vs S&P 500 (13W)-86.14%
Dividend Yield (TTM)0.36%
Beta2.05x
P/FCF (Annual)3.33x
Revenue / Share (TTM)$0.00
ROE (TTM)-169.40%
52-Week Low$0.18
Analyst Recommendations
Dec 2022
Jan 2023
Feb 2023
Mar 2023
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ERNAErnexa Therapeutics Inc. Common Stock | 9.43x | -99.83% | 83.51% | — | $0.20 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Ernexa Therapeutics is a biotechnology company developing cell-engineered medicines for cancer and autoimmune diseases. The company's proprietary platform converts induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) to create off-the-shelf cellular therapies, eliminating the need for patient-specific cell harvesting. This approach offers potential advantages in manufacturing scalability and cost-efficiency.